Abstract
The aim of this study was to investigate the importance of busulfan concentrations for short- and long-term survival in autologous (ABMT) and allogeneic (BMT) bone marrow transplant recipients. One hundred and seventy-three patients were included in the study; 87 ABMT and 85 BMT patients. All patients received busulfan 1 mg/kg four times daily for 4 days followed by cyclophosphamide 60 mg/kg/day for 2 days. Busulfan concentrations were measured and the mean concentration calculated for each patient. There was no difference in busulfan concentrations between BMT and ABMT patients. Patients who died before day 100 had significantly higher busulfan concentrations than patients surviving beyond day 100 (719 ng/ml vs 589 ng/ml; P < 0.02). bmt patients who had busulfan concentrations in the highest quartile had significantly worse disease-free survival (dfs) and survival compared to other patients. the transplant-related mortalities (trm) at 100 days were 29 and 14% in patients in the highest quartile and remaining patients, respectively. there was no difference in relapse incidence. high busulfan concentrations were associated with increased trm but no difference in either survival or dfs could be found for the abmt patients. monitoring of busulfan concentrations is important in reducing the risk for trm in patients undergoing bone marrow transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ljungman, P., Hassan, M., Békássy, A. et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20, 909–913 (1997). https://doi.org/10.1038/sj.bmt.1700994
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700994
Keywords
This article is cited by
-
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
Annals of Hematology (2021)
-
Comparison of Two Analytical Methods for Busulfan Therapeutic Drug Monitoring
European Journal of Drug Metabolism and Pharmacokinetics (2021)
-
Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT
Bone Marrow Transplantation (2019)
-
Decline of forced expiratory volume in 1 s after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use
International Journal of Hematology (2019)
-
The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients
Annals of Hematology (2018)